Navigation Links
CombinatoRx and Neuromed Sign Merger Agreement
Date:7/2/2009

    - Merger to Create a Sustainable Biotechnology Company: Brings Together
    Significant Product Assets, Unique Discovery Capabilities and Financial
    Resources -

CAMBRIDGE, MA and VANCOUVER, BC, July 2 /PRNewswire/ - CombinatoRx, Incorporated (NASDAQ: CRXX) and Neuromed Pharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced they have entered into a definitive merger agreement under which CombinatoRx and Neuromed will merge in an all-stock transaction. Under the terms of the merger agreement, CombinatoRx is expected to issue approximately 36 million new shares of its common stock to Neuromed stockholders with each party owning approximately 50% of the voting power of the merged organization upon closing. Relative ownership of CombinatoRx will then be adjusted based upon the outcome of the FDA's review of the NDA product candidate, Exalgo(TM).

This merger brings together the product assets and financial resources of both organizations, including potential Exalgo(TM) milestones and royalty revenue and Neuromed's proven drug development expertise, with the CombinatoRx portfolio of product candidates and its unique drug discovery capabilities. The rights to Exalgo(TM), designed to be a once-daily, oral hydromorphone treatment seeking FDA approval for chronic to severe pain, were recently acquired by Mallinckrodt Inc., a subsidiary of Covidien plc, for $15 million in upfront payments, additional development funding of up to $16 million to cover internal and external costs associated with Exalgo, an approval milestone of $30 million, which could potentially increase up to $40 million, and tiered royalties on Exalgo(TM) net sales after approval. Neuromed has filed a New Drug Application for Exalgo(TM) with the FDA, which has a November 22, 2009 PDUFA review date.

"By combining forces with Neuromed
'/>"/>

SOURCE Neuromed Pharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077
2. Neuromed Appoints Jeffrey Arcara and Gene Wright to Senior Management Team
3. Nfocus Neuromedical Receives CE Mark for the CardioVasc(TM) Stent-Graft and Delivery System
4. Nfocus Neuromedical Announces Acquisition of StarFire Medical
5. Neuromed Completes Enrollment for Phase 3 Chronic Low Back Pain Clinical Trial of NMED-1077
6. Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
7. Nfocus Neuromedical Elects Eric P. Milledge Chairman of Board
8. $10 Million Gift to Transform Neuromedicine at URMC
9. Neuromed Announces that Merck & Co., Inc. Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels
10. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
11. Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article from The ... Found to Release Natural Painkiller That Can Last 'For Five Weeks'" discusses the ... report, the new study showed that harvesting stem cell-rich bone marrow from the hip, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Illinois Health & Science (IHS) has ... , The acquisition includes all of IBAM NA’s cyclotron sites and research and development ... robust regionally located business, as well as a large manufacturing hub in Noblesville, Indiana,” ...
(Date:8/3/2015)... Ramon, CA (PRWEB) , ... August 03, 2015 ... ... leading global insurance brokerage firm, announced today that Joe Williams has joined its ... development, sales, and delivering HUB's differentiated service model to his clients. Mr. Williams ...
(Date:8/3/2015)... Portland, Ore. (PRWEB) , ... August 03, 2015 ... ... President of Government Programs, with accountability for overall performance of the company’s Medicare ... a key focus of Cambia’s strategy to deliver better health for members. In ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... leading provider of medical information, risk management and investigative services, has introduced ... direction toward focused, expert information solutions that improve business outcomes for its ...
Breaking Medicine News(10 mins):Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... Today, in light of a,recent study released by ... April is National STD Awareness Month, Congresswoman Stephanie ... introduced a bi-partisan,resolution urging the House of Representatives ... prevention, screening and treatment of,sexually transmitted diseases (STD)., ...
... Healthcare Realty,Trust Incorporated (NYSE: HR ) today announced ... closes, it will report results for the first,quarter of ... Central Time, Healthcare Realty Trust will,hold a conference call ... Company and industry trends. Simultaneously with,the conference call, a ...
... Awardee to be named at 6th International Stem Cell Symposium Seoul, Korea ... ... SEOUL, Korea, April 22 AlphaMed Press,publisher of the peer-reviewed journal STEM ... the,International Stem Cell Symposium, will be presented on June 20, 2008 in,Seoul, ...
... But doctors want more data, and device not yet approved ... -- A new kind of drug-coated stent was better at ... large-scale U.S. study of the device, researchers report. , "This ... the Xience stent is superior to the Taxus stent, in ...
... VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ), a ... treatment of peripheral vascular disease,explains interruption of its ... p.m. PT/5:00 p.m./ET. As a result of teleconference,vendor ... as planned., Interested parties are encouraged to ...
... parent of a sick child is,emotionally and physically draining. ... a world where there is very little,control and every ... (See video from CIGNA Healthcare at:, http://media.medialink.com/WebNR.aspx?story=34951 ... Leukemia Foundation called the,"Hope Binder" helps parents manage the ...
Cached Medicine News:Health News:Tubbs Jones Introduces Resolution Encouraging STD Prevention 2Health News:Healthcare Realty Trust Announces First Quarter Earnings Release Date and Conference Call 2Health News:Stem Cells(R) and International Stem Cell Symposium Present Annual Stem Cells(R) Young Investigator Award 2Health News:New Drug-Coated Stent Does Well in Early Trial 2Health News:New Drug-Coated Stent Does Well in Early Trial 3
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... prior year. Reported sales decreased 4% as currency reduced ... Net earnings per diluted share as reported (EPS) were ... EPS was $2.80 , an increase of 9% ...
(Date:7/30/2015)... 30, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... Development Agreements with Dexcom, Inc. to allow the ... the Dexcom G5 and G6 continuous glucose monitoring ... pump platform with Dexcom,s future CGM systems is ...
(Date:7/30/2015)... and VANCOUVER , July 30, ... announced today that it will report its second quarter ... management will host a conference call and live webcast ... of financial results, clinical development programs and a general ... log on to the Investor Relations page of the ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... FSH EIA Test is based ... solid phase enzyme-linked immunosorbent assay. ... monoclonal anti-FSH for solid phase ... anti-alpha FSH in the antibody-enzyme ...
Lyophilized, tri-level assayed human serum-based control, Low, intermediate and high levels, Lot-specific target values provided, Suitable for use with RIA, EIA and chemiluminescent,methodo...
... Hormone (FSH) is intimately involved in the ... of the gonadal tissues, which synthesize and ... The levels of circulating FSH is controlled ... feedback relationship. The FSH Quantitative Test ...
Complete product line for typing all classical HLA loci including A, B, C DRA, DRB1, DRB3, DRB4, DRB5, DQA, DQB1, DPA1, and DPB1....
Medicine Products: